Pivotal bioVenture Partners China
VC Fund
Shanghai, China
Pivotal bioVenture Partners China is a VC fund in Shanghai focused on Biotechnology and Health Care. An Investment Firm based In China.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Pivotal bioVenture Partners China invests in
Stages Pivotal bioVenture Partners China invests in
Countries Pivotal bioVenture Partners China invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 4 (67%)
- Health Care 3 (50%)
- Life Science 2 (33%)
- Pharmaceutical 2 (33%)
- Medical 1 (17%)
Stage
- Series B 3 (50%)
- Seed 2 (33%)
- Series A 1 (17%)
Country
- China 3 (50%)
- United States 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Vincent Cheung
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Heranova Lifesciences
|
Hekaiwei is a provider of innovative solutions for women's health. | $3.5M / Seed / Dec 28, 2023 | |
Arctic Vision
|
Arctic Vision is a China-based clinical-stage specialty ophthalmology company with a leading portfolio of breakthrough technologies. The Company's vision is to address ophthalmology's unmet needs through innovative therapies in China, Asia, and globally. Arctic Vision is established by top-tier life sciences investors and led by an eliteteam of ophthalmic industry veterans with substantial and compelling China and global experiences in R&D and commercialization of eye care products. | $100M / Series B / Mar 09, 2021 | |
Visen Pharmaceuticals
|
Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China. | $150M / Series B / Jan 08, 2021 | |
|
Arctic Vision
|
Arctic Vision is a China-based clinical-stage specialty ophthalmology company with a leading portfolio of breakthrough technologies. The Company's vision is to address ophthalmology's unmet needs through innovative therapies in China, Asia, and globally. Arctic Vision is established by top-tier life sciences investors and led by an eliteteam of ophthalmic industry veterans with substantial and compelling China and global experiences in R&D and commercialization of eye care products. | $32M / Series A / Jul 13, 2020 | |
OncXerna Therapeutics
|
OncXerna Therapeutics offers precision medicine using an innovative RNA-based biomarker platform.OncXerna Therapeutics is aiming to deliver next-generation precision medicine for a larger group of cancer patients by leveraging the company’s deep understanding of how to prospectively identify patients based on the dominant biology of their tumormicroenvironments. This allows OncXerna to pair those patients with OncXerna’s clinical-stage therapies with known mechanisms of action that directly address these biologies, to dramatically improve patient outcomes.The company was founded in 2018 and was formerly known as Oncologie. | $80M / Series B / Jun 10, 2019 | |
|
OncXerna Therapeutics
|
OncXerna Therapeutics offers precision medicine using an innovative RNA-based biomarker platform.OncXerna Therapeutics is aiming to deliver next-generation precision medicine for a larger group of cancer patients by leveraging the company’s deep understanding of how to prospectively identify patients based on the dominant biology of their tumormicroenvironments. This allows OncXerna to pair those patients with OncXerna’s clinical-stage therapies with known mechanisms of action that directly address these biologies, to dramatically improve patient outcomes.The company was founded in 2018 and was formerly known as Oncologie. | $16.5M / Seed / Jun 07, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Pivotal bioVenture Partners China invest in?
Pivotal bioVenture Partners China invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series B and Seed stage. Most of the 6 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Pivotal bioVenture Partners China?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Pivotal bioVenture Partners China?
The team at Pivotal bioVenture Partners China includes Vincent Cheung (Founder & Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
